Innovation & Technology for Biosimilar Development

A biosimilar is an organic item very like an affirmed natural item, known as a kind of perspective item, with no clinically significant contrasts as far as wellbeing and viability. In the U.S., if a natural compound exhibits practically identical information to a U.S. Nourishment and Drug Administration (FDA)- authorized item from expository, preclinical and clinical reviews, it will be acknowledged as a biosimilar after termination of trend-setter licenses through a curtailed course. Tradable natural items are likewise biosimilars, however should meet extra criteria to coordinate the reference item. Interchangeable can be substituted for the reference item without a medicine from a social insurance supplier.

  • Biosimilar Product Reimbursement and Pricing
  • Biosimilar Regulatory Updates and Legal Implications
  • Biosimilar Market Access and Commercialization

Related Conference of Innovation & Technology for Biosimilar Development

November 09-11, 2017

4th European Biopharma Congress

Vienna, Austria
August 20-22, 2018

9th Asian Biologics and Biosimilars Congress

Tokyo, Japan

Innovation & Technology for Biosimilar Development Conference Speakers

Recommended Sessions

Related Journals

Are you interested in